Compare MXL & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | SANA |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2010 | 2021 |
| Metric | MXL | SANA |
|---|---|---|
| Price | $19.19 | $4.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $20.25 | $7.83 |
| AVG Volume (30 Days) | 972.8K | ★ 3.2M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $423,372,000.00 | N/A |
| Revenue This Year | $30.54 | N/A |
| Revenue Next Year | $18.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $8.35 | $1.26 |
| 52 Week High | $25.73 | $6.55 |
| Indicator | MXL | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 57.10 |
| Support Level | $17.90 | $4.37 |
| Resistance Level | $19.12 | $4.92 |
| Average True Range (ATR) | 0.77 | 0.29 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 75.06 | 83.84 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.